Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 50 | 2025 | 948 | 12.500 |
Why?
|
| Kidney Failure, Chronic | 47 | 2025 | 953 | 11.620 |
Why?
|
| Peritoneal Dialysis | 9 | 2023 | 137 | 5.220 |
Why?
|
| Medicare | 18 | 2025 | 447 | 3.360 |
Why?
|
| Nephrologists | 4 | 2025 | 17 | 2.400 |
Why?
|
| Prospective Payment System | 5 | 2021 | 16 | 2.290 |
Why?
|
| United States | 44 | 2025 | 11675 | 1.950 |
Why?
|
| Ambulatory Care | 5 | 2021 | 412 | 1.850 |
Why?
|
| Hemodialysis, Home | 4 | 2022 | 13 | 1.850 |
Why?
|
| Economic Competition | 4 | 2023 | 14 | 1.670 |
Why?
|
| Ambulatory Care Facilities | 6 | 2021 | 241 | 1.460 |
Why?
|
| Health Facility Closure | 2 | 2021 | 8 | 1.370 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 697 | 1.360 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 256 | 1.340 |
Why?
|
| Health Care Sector | 3 | 2020 | 20 | 1.340 |
Why?
|
| Health Policy | 4 | 2020 | 232 | 1.320 |
Why?
|
| Nephrology | 4 | 2025 | 158 | 1.210 |
Why?
|
| Patient Readmission | 4 | 2017 | 425 | 1.180 |
Why?
|
| Reimbursement Mechanisms | 4 | 2023 | 35 | 1.150 |
Why?
|
| Hematinics | 2 | 2023 | 59 | 1.120 |
Why?
|
| Telemedicine | 2 | 2025 | 506 | 1.100 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2024 | 96 | 1.040 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 767 | 1.030 |
Why?
|
| Fee-for-Service Plans | 2 | 2016 | 18 | 1.020 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 482 | 1.000 |
Why?
|
| Medicaid | 6 | 2019 | 251 | 0.980 |
Why?
|
| Hemodiafiltration | 1 | 2025 | 18 | 0.920 |
Why?
|
| Financing, Government | 2 | 2023 | 32 | 0.910 |
Why?
|
| Humans | 67 | 2025 | 132201 | 0.910 |
Why?
|
| Health Expenditures | 4 | 2022 | 132 | 0.890 |
Why?
|
| Anemia | 2 | 2023 | 350 | 0.880 |
Why?
|
| Aged | 27 | 2025 | 21456 | 0.850 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2014 | 16 | 0.840 |
Why?
|
| Benzazepines | 2 | 2014 | 48 | 0.830 |
Why?
|
| Hospitalization | 4 | 2021 | 1902 | 0.810 |
Why?
|
| Vitamin D | 2 | 2018 | 183 | 0.810 |
Why?
|
| National Health Programs | 1 | 2023 | 21 | 0.790 |
Why?
|
| Registries | 8 | 2022 | 1591 | 0.770 |
Why?
|
| Health Care Costs | 3 | 2020 | 415 | 0.690 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 7 | 0.680 |
Why?
|
| Middle Aged | 25 | 2025 | 29007 | 0.660 |
Why?
|
| Insurance, Health | 2 | 2018 | 144 | 0.650 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2020 | 9 | 0.650 |
Why?
|
| Health Facility Merger | 2 | 2019 | 8 | 0.650 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2020 | 846 | 0.640 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 725 | 0.630 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 742 | 0.620 |
Why?
|
| Male | 36 | 2025 | 64979 | 0.620 |
Why?
|
| Reimbursement, Incentive | 2 | 2023 | 48 | 0.610 |
Why?
|
| Specialization | 1 | 2019 | 80 | 0.600 |
Why?
|
| Models, Organizational | 1 | 2019 | 45 | 0.590 |
Why?
|
| Safety-net Providers | 1 | 2019 | 70 | 0.590 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 571 | 0.590 |
Why?
|
| Female | 36 | 2025 | 70754 | 0.580 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 50 | 0.580 |
Why?
|
| Physician Assistants | 1 | 2019 | 78 | 0.560 |
Why?
|
| Commerce | 1 | 2018 | 57 | 0.560 |
Why?
|
| Cost-Benefit Analysis | 5 | 2025 | 576 | 0.550 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 139 | 0.540 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 143 | 0.530 |
Why?
|
| Physicians | 2 | 2023 | 640 | 0.520 |
Why?
|
| Insurance Coverage | 1 | 2017 | 127 | 0.510 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 216 | 0.510 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2087 | 0.500 |
Why?
|
| Hemoglobins | 2 | 2023 | 322 | 0.490 |
Why?
|
| Mobility Limitation | 1 | 2015 | 33 | 0.470 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 6 | 0.460 |
Why?
|
| Vascular Access Devices | 1 | 2014 | 38 | 0.440 |
Why?
|
| Office Visits | 1 | 2015 | 78 | 0.440 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 486 | 0.430 |
Why?
|
| Health Resources | 1 | 2015 | 135 | 0.410 |
Why?
|
| Pravastatin | 1 | 2013 | 22 | 0.400 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 36 | 0.390 |
Why?
|
| Cohort Studies | 8 | 2019 | 5173 | 0.390 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 573 | 0.380 |
Why?
|
| Health Care Reform | 3 | 2020 | 53 | 0.380 |
Why?
|
| Hyperparathyroidism | 1 | 2010 | 26 | 0.340 |
Why?
|
| Naphthalenes | 1 | 2010 | 38 | 0.340 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 491 | 0.330 |
Why?
|
| Residence Characteristics | 1 | 2013 | 286 | 0.330 |
Why?
|
| Adult | 13 | 2025 | 31600 | 0.330 |
Why?
|
| Ownership | 3 | 2019 | 35 | 0.320 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 1444 | 0.320 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 628 | 0.290 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17391 | 0.290 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 213 | 0.280 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2013 | 141 | 0.270 |
Why?
|
| Cost Savings | 2 | 2020 | 78 | 0.270 |
Why?
|
| Time Factors | 7 | 2019 | 6452 | 0.270 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 926 | 0.260 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1171 | 0.260 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 787 | 0.250 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 1062 | 0.230 |
Why?
|
| Parathyroid Hormone | 1 | 2025 | 83 | 0.230 |
Why?
|
| Stroke | 1 | 2013 | 1083 | 0.220 |
Why?
|
| Forearm | 1 | 2024 | 39 | 0.220 |
Why?
|
| Qualitative Research | 2 | 2025 | 662 | 0.220 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3760 | 0.210 |
Why?
|
| Ferritins | 1 | 2023 | 109 | 0.200 |
Why?
|
| Markov Chains | 2 | 2013 | 101 | 0.200 |
Why?
|
| Disease Progression | 3 | 2013 | 2230 | 0.190 |
Why?
|
| Travel | 1 | 2023 | 124 | 0.190 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 94 | 0.190 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 26 | 0.180 |
Why?
|
| Iron | 1 | 2023 | 302 | 0.170 |
Why?
|
| Neoplasms | 1 | 2015 | 2961 | 0.160 |
Why?
|
| China | 1 | 2021 | 290 | 0.160 |
Why?
|
| Propensity Score | 1 | 2021 | 255 | 0.160 |
Why?
|
| Health Facilities, Proprietary | 1 | 2019 | 3 | 0.160 |
Why?
|
| Data Collection | 1 | 2022 | 391 | 0.160 |
Why?
|
| Benzofurans | 1 | 2019 | 24 | 0.160 |
Why?
|
| Logistic Models | 2 | 2016 | 1841 | 0.160 |
Why?
|
| Quinoxalines | 1 | 2019 | 38 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2022 | 13028 | 0.160 |
Why?
|
| Medically Uninsured | 1 | 2019 | 78 | 0.150 |
Why?
|
| Patient Care | 1 | 2020 | 99 | 0.150 |
Why?
|
| Ezetimibe | 1 | 2019 | 94 | 0.150 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 61 | 0.150 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 311 | 0.150 |
Why?
|
| Outpatients | 1 | 2020 | 275 | 0.140 |
Why?
|
| Imidazoles | 1 | 2019 | 219 | 0.140 |
Why?
|
| Indians, North American | 1 | 2018 | 68 | 0.140 |
Why?
|
| Central Venous Catheters | 1 | 2018 | 48 | 0.140 |
Why?
|
| Risk Factors | 4 | 2018 | 10944 | 0.140 |
Why?
|
| Policy Making | 1 | 2018 | 62 | 0.140 |
Why?
|
| Pandemics | 1 | 2025 | 1186 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 674 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2018 | 295 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2025 | 739 | 0.130 |
Why?
|
| Employment | 1 | 2018 | 69 | 0.130 |
Why?
|
| Program Development | 1 | 2018 | 191 | 0.130 |
Why?
|
| Physician's Role | 1 | 2019 | 168 | 0.130 |
Why?
|
| Primary Health Care | 1 | 2023 | 801 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 439 | 0.130 |
Why?
|
| Graft Survival | 1 | 2018 | 473 | 0.130 |
Why?
|
| Kidney | 4 | 2024 | 1338 | 0.120 |
Why?
|
| Cause of Death | 1 | 2018 | 509 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2018 | 456 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2016 | 277 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 875 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 370 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 1233 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2019 | 576 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 162 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2019 | 823 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 700 | 0.100 |
Why?
|
| Risk | 2 | 2013 | 761 | 0.100 |
Why?
|
| Public Health | 1 | 2016 | 280 | 0.100 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1085 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2013 | 63 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 7123 | 0.100 |
Why?
|
| Hypertension, Renal | 1 | 2012 | 35 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 1177 | 0.100 |
Why?
|
| Drug Costs | 1 | 2013 | 65 | 0.100 |
Why?
|
| Young Adult | 4 | 2019 | 9965 | 0.100 |
Why?
|
| Heparin | 1 | 2014 | 212 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 187 | 0.100 |
Why?
|
| Proteinuria | 1 | 2012 | 111 | 0.090 |
Why?
|
| Age of Onset | 1 | 2013 | 626 | 0.090 |
Why?
|
| Morbidity | 1 | 2012 | 256 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2013 | 179 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2016 | 490 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1461 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1671 | 0.090 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2015 | 515 | 0.080 |
Why?
|
| Health Status | 1 | 2013 | 408 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2014 | 519 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2014 | 511 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 554 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2013 | 1255 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 1128 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1354 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 447 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2014 | 610 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2398 | 0.070 |
Why?
|
| Arm | 1 | 2024 | 77 | 0.050 |
Why?
|
| Hypertension | 1 | 2013 | 1398 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 5410 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2553 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 330 | 0.040 |
Why?
|
| Carbamates | 1 | 2019 | 68 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 71 | 0.040 |
Why?
|
| Amides | 1 | 2019 | 91 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 138 | 0.040 |
Why?
|
| Unemployment | 1 | 2018 | 22 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2019 | 272 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2019 | 284 | 0.030 |
Why?
|
| Incidence | 1 | 2025 | 3377 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2018 | 225 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 20557 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 135 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2016 | 135 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 141 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 2702 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1610 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2019 | 802 | 0.020 |
Why?
|
| South Carolina | 1 | 2011 | 10 | 0.020 |
Why?
|
| Georgia | 1 | 2011 | 39 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3091 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 67 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 2920 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 116 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 796 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 1766 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2011 | 424 | 0.020 |
Why?
|